 First Preclinical Data for IGM-2644 and IGM-2537 Featured in Poster Presentations MOUNTAIN VIEW, Calif., Dec. 11, 2022 GLOBE NEWSWIRE IGM Biosciences, Inc. Nasdaq: IGMS, a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced the presentation of data from IGMs expanding portfolio of T cell engagers for hematologic malignancies, including IGM-2644, ... The post IGM Biosciences Presents Data from T cell Engager Portfolio for Hematologic Mali... 